Trial Profile

A prospective, open label study of safety and efficacy of neoadjuvant PD-1 inhibitors (Camrelizumab 200mg or Sintilimab 200 mg or Tislelizumab 200 mg) with chemotherapy for resectable esophageal squamous carcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Sintilimab (Primary) ; Tislelizumab (Primary)
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

22 May 2022 New trial record
13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com